The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2018
Filed:
Apr. 23, 2015
Julius-maximilians-universität Würzburg, Würzburg, DE;
Alexandra Friedrich, Würzburg, DE;
Jürgen Groll, Würzburg, DE;
Hermann Koepsell, Höchberg, DE;
Maike Veyhl-Wichmann, Würzburg, DE;
Julius-Maximilians-Universität Würzburg, Würzburg, DE;
Abstract
The present invention relates to a pharmaceutical composition comprising a (poly)peptide which comprises or consists of QEP or a QEP derivative thereof a nucleic acid molecule encoding said (poly)peptide or a vector comprising said nucleic acid molecule, for use in the prevention or in the treatment of a disease or disorder caused by, physiologically linked to or associated with glucose and/or galactose uptake, wherein said pharmaceutical composition is to be administered under a high-sugar condition. Furthermore, the pharmaceutical composition of the invention is for use in increasing insulin sensitivity. The invention further relates to a food composition comprising said (poly)peptide. The invention further relates to a method of screening for and/or identifying a compound suitable to prevent or treat said disease or disorder under a high-sugar condition. The invention further relates to a method of screening for and/or identifying a compound which modulates ornithine decarboxylase (ODC), which is capable of inhibiting (SGLT1-mediated) glucose and/or galactose uptake into a cell expressing ODC and/or which is capable of increasing the inhibitory effect of an inhibitor of glucose and/or galactose uptake into a cell expressing ODC. The invention further relates to a method for predicting a patients non-response or response to said (poly)peptide, to a method for stratifying a patient for prevention or treatment with said (poly)peptide and to a kit for determining whether a patient suffering from said disease or disorder is a non-responder or responder to said polypeptide. The invention further relates to a method of developing and/or designing a compound/drug suitable to prevent or treat said disease or disorder.